Paul David Mozley

Radiopharmaceutical and biomarker development leader with a 30 year record of advancing first in human imaging agents, shaping regulatory strategy, and driving clinical translation for oncology, neurology, and inflammation therapeutics. Architect of large, complex radiopharmaceutical portfolios across academia, big pharma, and venture backed biotech. Tenured professor, prolific scientific author, and physician sponsor of more than 20 INDs. Recognized for transforming imaging science into decisive drug development tools, revitalizing compliance systems, and guiding organizations through pivotal regulatory milestones.